Key facts
- Angiex’s last known valuation is $182.6M (Aug 2021).
- It has raised $98.7M across 2 recorded rounds; the latest was Early Stage VC ($22.0M) in Jul 2025.
- Notable investors include MassChallenge, Mana Ventures, Gaingels, Keiretsu Forum, K5 Global — 19 tracked in total.
- Angiex has filed 3 Form Ds with the SEC since 2017, most recently Sep 2025 ($22.0M sold to 137 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 19 names
- ·Watchlist + deal alerts for Angiex
Funding rounds
2 roundsAbout Angiex
Developer of vascular-targeted biotherapeutics designed for the treatment of solid cancers and other diseases of pathological angiogenesis. The company's antibody-drug conjugate therapy for solid cancers enables rapid development of nuclear-delivered antibody-drug conjugates that deliver conjugated payloads directly to the nucleus in tumor cells and to the activated endothelium of cancers and inflamed vessels, enabling healthcare providers to cure human cancers such as pancreatic, lung, and liver cancers and glioblastoma multiforme.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2015
- Employees
- 5
- Website
- angiex.com/
- Ownership
- Privately Held (backing)
Angiex doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Angiex shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Angiex in its N-PORT filings yet. We sweep new filings monthly.